Newcastle Magnetic Resonance Centre


A multicentre, multi-international, randomised, double blind, placebo controlled, parallel group study to evaluate the efficacy and safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as treatment in patients with Huntington's disease

A Multicentre, Multinational, Randomized, Double-Blind, Placebo-Controlled,Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5,1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease. Phase II, to evaluate the efficacy and safety of daily oral administration of laquinimod (0.5 mg and 1.0 mg) in patients with HD. Study participants will be randomized in a 1:1:1 ratio to receive laquinimod 0.5 mg/day or 1.0 mg/day or matching placebo for 52 weeks.
All subjects will undergo an initial PET scan, followed by an MRI scan at both baseline and Month 12. Changes from baseline in brain atrophy as defined by the percentage change in volume in whole brain volume and white-matter volume at Month 12/ET (early termination) and absolute change in ventricular volume at Month 12/ET (Early termination) will be evaluated.